Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Cancer cell or component thereof
Patent
1995-06-05
1999-11-30
Hutzell, Paula F.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Cancer cell or component thereof
435 723, 5303877, 5303897, 530828, A61K 3512, G01N 3353, C07K 1630
Patent
active
059938285
ABSTRACT:
A method for inducing or enhancing in a human subject the production of antibodies reactive with the polypeptide subunit of Urinary Tumor Associated Antigen having a molecular weight of about 90 to 100 kD after reduction by .beta.-mercaptoethanol and separation by SDS-polyacrylamide gel electrophoresis is disclosed. The method comprises administering to the subject an effective dose of a composition comprising inactivated tumor cells having Urinary Tumor Associated Antigen on the cell surface and at least one tumor associated antigen selected from the group consisting of GM-2, GD-2, Fetal Antigen and Melanoma Associated Antigen.
REFERENCES:
patent: 4233286 (1980-11-01), Soothill et al.
patent: 4348376 (1982-09-01), Goldenberg
patent: 4557931 (1985-12-01), Irie et al.
patent: 4562160 (1985-12-01), Real et al.
patent: 4753884 (1988-06-01), Kit et al.
patent: 4806628 (1989-02-01), Albino et al.
patent: 4810781 (1989-03-01), Hollinshead et al.
patent: 4895817 (1990-01-01), Witter
patent: 5030621 (1991-07-01), Bystryn
patent: 5194384 (1993-03-01), Bystryn
patent: 5427664 (1995-06-01), Stoev et al.
patent: 5484596 (1996-01-01), Hanna et al.
Bystryn et al., "Preparation and Characterization of a Polyvalent Human Melanoma Antigen Vaccine," Journal of Biological Response Modifiers, 5:211-224, 1986.
Dunbar et al., "Protein Analysis Using High-Resolution Two-Dimensional Polyacrylamide Gel Electrophoresis," Methods in Enzymology, 182:441-443, 1990.
Euhus et al., "A Murine Monoclonal Antibody to a Glycoprotein Tumor Associated Antigen in Sera and Urine of Melanoma Patients," AACR, Abstract No. 1566, 1988.
Euhus et al., "Demonstration and Isolation of a Glycoprotein Tumor Associated Antigen from Sera of Melanoma Patients," Proceedings of American Society of Clinical Oncology, Abstract No. 169, 7:44, Mar., 1988.
Euhus et al., "Induction of antibodies to a tumor-associated antigen by immunization with a whole melanoma cell vaccine," Cancer Immunol. Immunother., 29:247-254, 1989.
Gupta et al., "Immunologic Similarity Between Tumor-Associated Antigens Detected in Urine of Melanoma Patients and Those Expressed by Melanoma Cells," Proceedings of American Society of Clinical Oncology, Abstract No. C-35, p. 9, Mar. 1984.
Gupta et al., "Increase in Antibody Level to a Tumor Associated Antigen in Melanoma Patients Undergoing Immunotherapy with a Tumor Cell Vaccine," Proceedings of American Society of Clinical Oncology, Abstract No. 979, 6:249, Mar., 1987.
Huth et al., "Purification of Antigens From Urine of a Sarcoma Patient by Affinity Chromatography," Journal of Surgical Oncology, 18:237-247, 1981.
Paulie et al., "Monoclonal antibodies to antigens associated with transitional cell carcinoma of the human urinary bladder," Cancer Immunol. Immunother., 17:173-179, 1984.
Rote et al., "Determination of Incidence and Partial Characterization of Tumor-Associated Antigens Found in the Urine of Patients Bearing Solid Tumors," Int. J. Cancer, 26:203-210, 1980.
Wong et al.,"Demonstration of a Well-Characterized Tumor-Associated Antigen on Melanoma Cell Surface," Journal of Surgical Oncology, 38:147-150, 1988.
Balch and Houghton, eds., "Melanoma vaccines," In: Cutaneous Melanoma, J.B. Lippincott Company, PA, 42:542-559, 1989.
Embleton et al., "Immunological monitoring in a controlled trial of immunotherapy in stage lib malignant melanoma," Br. J. Cancer, 37:497-504, 1978.
Euhus et al., "Association betweem allo-immunoreactiveand xeno-immunoreactive subunits of a glycoprotein tumor-associatedantigen," Cancer Immunol. Immunother., 32;214-220, 1990.
Euhus et al., "Characterization of a 90-100kDa tumor-associated antigen in the sera of melanoma patients," Int. J. Cancer, 45:1065-1070, 1990.
Euhus et al., "Effects of melanoma cell vaccine on levels of antibody to a tumor associated antigen in melanoma patients," Immunology, Proceedings of AACR, Abstract 28:349, 1987.
Foshag et al., "Specific cell mediated cytotoxicity in melanoma patients receiving melanoma cell vaccine (MCV) in combination with various biological response modifiers (BRM)," Proc. Amer. Assoc. Cancer Res., 30:344, 1989.
Foshag et al., "T-Cell cytotoxicity in melanoma patients receiving active specific-immunotherapy (ASI) and correlation to clinical outcome," Oncology, 430-431, publication date unknown.
Gupta et al., "Correlation of humoral immune response to a melanoma tumor associated antigen with survival of melanoma patients receiving active specific immunotherapy," Proc. Amer. Assoc. Cancer Res., Abstract, 30:344, 1989.
Gupta et al., "Detection of tumor associated antigen in urine of melanoma patients by allogenic antibody," FASEB Abstract Form, 1987.
Gupta and Morton, "In vitro production of antibodies to a melanoma tumor associated antigen by Epstein-Barr virus transformed human lymphoblastoid cells," Poster Presentation at the Annual Meeting of the American Association for Cancer Research, 1987.
Gupta and Morton, "Immunochemical characterization of fetal antigen isolated from spent medium of a human melanoma cell line," JNCI, 70(6):993-1004, 1983.
Gupta and Morton, "Monoclonal antibody-based ELISA to detect glycoprotein tumor-associated-antigen-specific immune complexes in cancer patients," J. Clin. Lab. Anal., 6:329-336, 1992.
Gupta and Morton, "Studies of a melanoma tumor-associated antigen detected in the spent culture medium of a human melanoma cell line by allogenic antibody. I. Purification and development of a radioimmunoassay," JNCI, 72(1):67-74, 1984.
Gupta and Morton, "Studies of a melanoma tumor-associated antigen detected in the spent culture medium of a human melanoma cell line by allogeneic antidoby. II. Immunobiologic characterization," JNCI, 72(1):75-82, 1984.
Gupta and Morton, "Studies of a melanoma tumor-associated antigen detected in the spent culture medium of a human melanoma cell line by allogeneic antibody. III. Physiochemical properties," JNCI, 72(1):83-92, 1984.
Hammerling et al., "The Influence of major histocompatibility complex class I antigens on tumor growth and metastasis," Biochimica et Biophysica Acta, 907:245-259, 1987.
Hayashi et al., "Cytotoxic T cell lines recognize autologous and allogenic melanomas with shared or cross-reactive HLA-A," Cancer Immunol. Immunother., 34:419-425, 1992.
Hoon et al., "A prospective randomized trial of immunomodulation with low dose cyclophosphamide (CYP) in patients receiving active specific immunotherapy with melanoma cell vaccine (MCV)," Melanoma, Proceedings of ASCO, 6:212, 1987.
Hoon et al.,"A randomized trial of immunomodulation with varous low dosages of cyclophosphamide in patients receiving active specific immunotherapy with melanonma cell vaccine," Immunology, Proceedings of AACR, 29:413, 1988.
Hoon et al., "Mixed lymphocyte-tumor reaction and delayted type hypersensitivity in patients receiving specific immunotherapy," Immunology, Proceedings of the American Association for Cancer Research, 31:253, 1990.
Hoon et al., "Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide," Cancer Research, 50:5358-5364, 1990.
Hoover et al., "Therapy of spontaneous metastases with an autologous tumor vaccine in a Guinea pig model, " J. Surg. Res., 30(4):409-415, 1981.
Hunt et al., "Complement-dependentlysis of tumor cells by a baboon IgM antibody to a tumor-associated antigen," Cancer Immunol. Immunother., 34:377-382, 1992.
Huth et al., "Relationship of tumor-associated urinary antigens to disease recurrence in melanoma patients," Surgical Oncology, 417-419, published date unknown.
Irie et al., "Antibodies to tumor-associated gangliosides (GM2 and GD2): Potential for suppression of melanoma recurence," In: Basic Mechanisms and Clinical Treatment of Tumor Metastasis, 21:371-383, 1985.
Irie et al., "Human monoclonal antibody to ganglioside GM2 for melanoma treatment," Reprinted for The Lancet, 786-787, 1989.
Irie et al., "Humoral immune response to melanoma-associated membrane antigen and fetal brain antigen demonstrated by indirect membrane Immunofluorescence. I," Cancer Immunol
Hutzell Paula F.
Johnson Nancy A.
LandOfFree
Tumor associated antigen compositions and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tumor associated antigen compositions and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor associated antigen compositions and methods will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1668277